Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 1-Year High at $51.68

Share on StockTwits

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)’s stock price reached a new 52-week high during trading on Tuesday . The company traded as high as $51.68 and last traded at $50.60, with a volume of 35950 shares traded. The stock had previously closed at $48.17.

A number of equities analysts recently commented on the company. BidaskClub upgraded Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, October 9th. Chardan Capital increased their price objective on Arrowhead Pharmaceuticals from $32.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. ValuEngine downgraded Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Piper Jaffray Companies increased their price objective on Arrowhead Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a report on Sunday, October 20th. Finally, Robert W. Baird downgraded Arrowhead Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $39.00 price objective on the stock. in a report on Thursday, October 24th. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $49.40.

The stock has a market cap of $4.50 billion, a P/E ratio of -78.34 and a beta of 1.68. The business has a 50-day simple moving average of $37.43 and a 200-day simple moving average of $29.71.

In other Arrowhead Pharmaceuticals news, Director Michael S. Perry sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $28.90, for a total transaction of $2,890,000.00. Following the completion of the sale, the director now owns 121,000 shares of the company’s stock, valued at $3,496,900. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Kenneth Allen Myszkowski sold 37,884 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $40.85, for a total value of $1,547,561.40. Following the completion of the sale, the chief financial officer now directly owns 351,420 shares of the company’s stock, valued at $14,355,507. The disclosure for this sale can be found here. Insiders have sold 350,104 shares of company stock valued at $10,783,025 in the last ninety days. Company insiders own 4.80% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of ARWR. Arlington Capital Management Inc. bought a new position in Arrowhead Pharmaceuticals in the third quarter worth $823,000. Mason Street Advisors LLC increased its position in Arrowhead Pharmaceuticals by 2.2% in the third quarter. Mason Street Advisors LLC now owns 32,360 shares of the biotechnology company’s stock worth $912,000 after purchasing an additional 711 shares during the period. Tower Research Capital LLC TRC increased its position in Arrowhead Pharmaceuticals by 2,008.0% in the third quarter. Tower Research Capital LLC TRC now owns 8,453 shares of the biotechnology company’s stock worth $238,000 after purchasing an additional 8,052 shares during the period. Alps Advisors Inc. acquired a new stake in Arrowhead Pharmaceuticals in the third quarter worth about $348,000. Finally, SG Americas Securities LLC increased its position in Arrowhead Pharmaceuticals by 239.1% in the third quarter. SG Americas Securities LLC now owns 83,005 shares of the biotechnology company’s stock worth $2,339,000 after purchasing an additional 58,527 shares during the period. 72.30% of the stock is owned by institutional investors.

About Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.

See Also: Stock Symbols, CUSIP and Other Stock Identifiers

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Ultra Electronics  Given New GBX 2,200 Price Target at JPMorgan Chase & Co.
Ultra Electronics Given New GBX 2,200 Price Target at JPMorgan Chase & Co.
Redrow  Price Target Increased to GBX 710 by Analysts at Liberum Capital
Redrow Price Target Increased to GBX 710 by Analysts at Liberum Capital
Spirax-Sarco Engineering  Receives Equal weight Rating from Morgan Stanley
Spirax-Sarco Engineering Receives Equal weight Rating from Morgan Stanley
Celsius  Shares Up 5.8%
Celsius Shares Up 5.8%
Allogene Therapeutics  Trading Up 6.3%
Allogene Therapeutics Trading Up 6.3%
SandRidge Energy  Stock Price Up 7.2%
SandRidge Energy Stock Price Up 7.2%


© 2006-2019 Ticker Report